T cell immunoglobulin and mucin domain-3 (TIM-3) represents an imperative immune checkpoint pivotal in regulating standard immune responses, yet opportunistically exploited by tumor cells to elude immune surveillance. Predominantly found on immune cells, particularly on dysfunctional and depleted T cells, TIM-3's interaction with its ligands precipitates a suppression of T cell activity. Enter antagonistic ligand-blocking anti-TIM-3 antibodies, such as M6903, which harbor immense potential to counteract T cell inhibition, reignite antigen-specific T cell functionality, and bolster the immune system's anti-tumor efficacy. M6903 stands out as a fully human anti-TIM-3 antibody devoid of effector function but boasting exceptional affinity and specificity towards TIM-3. Notably, M6903's pivotal action lies in obstructing the binding of TIM-3 to three of its ligands—phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9).